Inhibición de la angiogénesis: - page 20

Demographics and Baseline Characteristics

Were Balanced Between Treatment Arms

Nintedanib + docetaxel (n=655)

Placebo + docetaxel (n=659)

Reck M, et al.

Lancet Oncol

. 2014;15:143-55.

ECOG PS = Eastern Cooperative Oncology Group performance status.

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,10,11,12,13,14,15,16,17,18,19 21,22,23,24,25,26,27,28,29,30,...57